mRNA Biology Modulators Pipeline
Anima's wholly owned pipeline of mRNA biology modulators is in Immunology (Lung fibrosis lead compound advancing in preclinical stage), in Oncology (Solid tumors lead compounds entering preclinical stage and additional programs against Leukemia and Neuroblastoma), in Neuroscience (Alzheimer's disease and Pain).
In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly, Takeda Pharmaceuticals, and Abbvie.
| Indication | Target | Discovery |
Optimization |
IND enabling |
|
|---|---|---|---|---|---|
Immunology |
|||||
| Lung fibrosis | 1 | ||||
| Multiple fibrosis | 2 | ||||
| Multiple fibrosis | 3 | ||||
| Undisclosed |  |
4 | |||
Oncology |
|||||
| Solid tumors | 5 | ||||
| Solid tumors | 6 | ||||
| Leukemia | 7 | ||||
| Neuroblastoma | 8 | ||||
| Solid tumors | 9 | ||||
| Undisclosed | |
10 | |||
| Undisclosed | 11 | ||||
Neuroscience |
|||||
| Alzheimer | 12 | ||||
| Pain | 13 | ||||
| Undisclosed | 14 | ||||
| Undisclosed |  |
15 | |||
| Undisclosed | 16 | ||||
| Huntington | 17 | ||||
| Undisclosed |  |
18 | |||
| Undisclosed | 19 | ||||
| Undisclosed | 20 | ||||
| Area | Indication | Target | Discovery |
Optimization |
IND enabling |
||
|---|---|---|---|---|---|---|---|
| Immunology | Lung fibrosis | 1 | |||||
| Multiple fibrosis | 2 | ||||||
| Multiple fibrosis | 3 | ||||||
| Undisclosed | |
4 | |||||
| Oncology | Solid tumors | 5 | |||||
| Solid tumors | 6 | ||||||
| Leukemia | 7 | ||||||
| Neuroblastoma | 8 | ||||||
| Solid tumors | 9 | ||||||
| Undisclosed | |
10 | |||||
| Undisclosed | 11 | ||||||
| Neuroscience | Alzheimer | 12 | |||||
| Pain | 13 | ||||||
| Undisclosed | 14 | ||||||
| Undisclosed | |
15 | |||||
| Undisclosed | 16 | ||||||
| Huntington | 17 | ||||||
| Undisclosed | |
18 | |||||
| Undisclosed | 19 | ||||||
| Undisclosed | 20 | ||||||